# Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

> **NCT07486687** · PHASE3 · NOT_YET_RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 1000 (estimated)

## Conditions studied

- Triple Negative Breast Cancer (TNBC), Early Setting
- Early Stage Triple-Negative Breast Carcinoma
- Triple -Negative Breast Cancer
- Breast Cancer Stage II
- Breast Cancer Stage III

## Interventions

- **DRUG:** Standard of care plus pembrolizumab
- **DRUG:** Standard of care (capecitabine or olaparib)

## Key facts

- **NCT ID:** NCT07486687
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2032-04
- **Final completion:** 2036-04
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486687, "Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07486687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*